Lv13
38 积分 2023-07-26 加入
Long-Term Follow-Up of Chidamide With Chemotherapy in Untreated Peripheral T-Cell Lymphoma: One Single Center Real-World Study in China
1天前
已完结
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study
1天前
已完结
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)
2天前
已完结
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
5天前
已完结
Teclistamab plus Daratumumab in Relapsed Refractory Multiple Myeloma
5天前
已完结
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
8天前
已完结
The effect of haemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma
15天前
已完结
Baseline inflammation indexes and neutrophil‐to‐LDH ratio for prediction of the first mobilization failure without plerixafor‐based regimens in multiple myeloma and lymphoma patients: A single‐center retrospective study
21天前
已完结
Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified By Exposure to Lenalidomide or Anti-CD38 Therapy and Double-Class Refractory Status: A Retrospective Electronic Health Record Database Study
9个月前
已关闭
皖公网安备34019202002308
